Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
Nasdaq Breaks Above 5,000
16:03 - March 3 -- On “Before The Bell,” Ritholtz Wealth Management Chairman Barry Ritholtz and Bloomberg’s Alix Steel and Betty Liu discuss today’s top trending news stories. They speak on “In The Loop.”
  • Lumber Liquidators’ Stock Plunges
  • Ford Misses Estimates, U.S. Light-Vehicle Sales Fell 2%
  • Three Ways You Will Never Be Like Warren Buffett